Ma Fu-Zhi, Zhu Lin, Li Meng, Tang Ze-Wei, Yu Xiao-Hong, Zhang Cong-En, Ma Zhi-Jie
Department of Pharmacy,Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Front Chem. 2025 Aug 28;13:1635781. doi: 10.3389/fchem.2025.1635781. eCollection 2025.
associated diarrhea (CDAD) is a growing healthcare concern with limited effective treatments. 6-Gingerol, a major bioactive compound in ginger, exhibits notable antibacterial and anti-inflammatory properties, making it a potential alternative therapy. This study combines and approaches to evaluate its efficacy against CDAD. assays determined the half-maximal inhibitory concentration (IC) and minimum inhibitory concentration (MIC) of 6-Gingerol against , which were 61.99 μM and 173.3 μM, respectively, indicating direct antibacterial activity. , a mouse model of CDAD was used to assess the therapeutic effects of 6-Gingerol. Outcomes included clinical symptoms, load, inflammation, intestinal barrier integrity, gut microbiota composition, and short-chain fatty acids (SCFAs) levels. The results showed that in the CDAD mouse model, high-dose 6-Gingerol significantly alleviated CDAD symptoms, reduced load ( < 0.001), improved gut barrier function, and suppressed intestinal inflammation. Although it did not notably increase microbial diversity, 6-Gingerol modulated gut microbiota structure-markedly increasing beneficial bacteria such as ( < 0.01) and , while reducing harmful bacteria including and . Targeted quantification revealed restored levels of key SCFAs, particularly acetate ( < 0.001), butyrate ( < 0.01), and valerate ( < 0.001), which are closely linked to gut health and recovery from CDAD. In summary, 6-Gingerol exerts therapeutic effects against CDAD through direct inhibition of , regulation of gut microbiota, restoration of SCFA levels, and protection of the intestinal barrier, highlighting its potential as a novel natural treatment for CDAD.
难辨梭菌相关性腹泻（CDAD）是一个日益引起医疗保健关注的问题，有效治疗方法有限。6-姜酚是生姜中的一种主要生物活性化合物，具有显著的抗菌和抗炎特性，使其成为一种潜在的替代疗法。本研究结合[具体方法1]和[具体方法2]方法来评估其对CDAD的疗效。[具体实验1]分析确定了6-姜酚对[目标菌株]的半数最大抑制浓度（IC）和最小抑制浓度（MIC），分别为61.99μM和173.3μM，表明其具有直接抗菌活性。[具体实验2]中，使用CDAD小鼠模型评估6-姜酚的治疗效果。结果包括临床症状、[目标菌株]载量、炎症、肠道屏障完整性、肠道微生物群组成和短链脂肪酸（SCFAs）水平。结果表明，在CDAD小鼠模型中，高剂量6-姜酚显著减轻了CDAD症状，降低了[目标菌株]载量（P<0.001），改善了肠道屏障功能，并抑制了肠道炎症。虽然6-姜酚没有显著增加微生物多样性，但它调节了肠道微生物群结构——显著增加了有益细菌，如[有益菌1]（P<0.01）和[有益菌2]，同时减少了包括[有害菌1]和[有害菌2]在内的有害细菌。靶向定量显示关键SCFAs水平恢复，特别是乙酸盐（P<0.001）、丁酸盐（P<0.01）和戊酸盐（P<0.001），它们与肠道健康和从CDAD中恢复密切相关。总之，6-姜酚通过直接抑制[目标菌株]、调节肠道微生物群、恢复SCFA水平和保护肠道屏障对CDAD发挥治疗作用，突出了其作为CDAD新型天然治疗方法的潜力。
